Introduction
The advent of continuous human leukemia-lymphoma cell lines as a rich resource of abundant, accessible, replenishable and manipulable living cells has contributed significantly to a better understanding of the pathophysiology of hematopoietic tumors. 1 For instance in the analysis of non-random chromosomal translocations, cell lines have clearly been very important genetic resources. 2 The occurrence of defined chromosomal translocations in specific subtypes of leukemia and lymphoma strongly suggests that these structural alterations play an important role in the process of tumorigenesis. Translocations may activate nearby cellular genes involved in the control of cell survival, apoptosis, activation, proliferation or differentiation. A large number of the translocated genes appear to encode transcription factors, the expression of which might become deregulated due to the influence of regulatory elements in the T cell or B cell antigen receptor genes.
One other general type of chromosomal translocation by which genes can be activated results in the synthesis of fusion genes. Here, chimera proteins containing portions of two different proteins are generated following exon-exon juxtaposition of two genes lying at the sites of translocation. The list of such tumor-associated fusion genes generated by specific translocations has tremendously increased over the last years. For many translocations, DNA spanning the breakpoint was isolated by using cell lines carrying the particular abnormality (for a detailed review, see Ref. cations are stable in vitro, cell lines carrying them are widely used as sources of RNA/DNA for positive controls in PCR assays, forming part of the basic 'toolkit' for clinical diagnostic laboratories. 3 Here, we describe the establishment and characteristics of the new human leukemia cell line MUTZ-5, which carries the translocation t(12;13). These cells may serve as material for the further analysis of this chromosomal abnormality.
Materials and methods

Case report
A 26-year-old man was diagnosed as having B cell precursor acute lymphoblastic leukemia (BCP-ALL). The patient had been diagnosed and treated in the Middle East. Complete remission was achieved, but he then relapsed. The same chromosomal abnormality was also observed in the relapse sample. The patient was then referred to the Royal Marsden Hospital, London, UK. Peripheral blood cells taken at relapse were purified and stored frozen in liquid nitrogen.
Cell culture
Cells from one of the frozen peripheral blood samples were thawed, washed and cultured in a 24-well plate (Nunc, Wiesbaden, Germany) at an initial density of 4 × 10 6 cells/ml in McCoy's 5A medium (Life Technologies, Gibco BRL, Karlsruhe, Germany) supplemented with 20% heat-inactivated fetal bovine serum (FBS; Sigma, Deisenhofen, Germany) and 5 ng/ml PIXY-321 (a fusion protein of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) kindly provided by Immunex, Seattle, WA, USA) at 37°C in an atmosphere of 5% CO 2 in air. The medium was changed regularly every 2 days. The cells were examined daily under the inverted microscope and the cell number was counted weekly in a standard hematocytometer using trypan blue dye exclusion. After about 3 months, the cell number began to increase slowly, but steadily and cells could also be grown in flasks. It was then noted that the cells were cytokine-independent and the externally added PIXY-321 was omitted from the complete medium.
Characterization of MUTZ-5 cells
We attempted to characterize the cells as detailed as necessary, as outlined previously. 1, 4 Details of the various methods employed for the identity and quality control and characterization of MUTZ-5 cells have been described elsewhere: DNA fingerprinting, 5 immunophenotyping using flow cytometry and fluorescence microscopy, 6 cytokine proliferation assay, immunoglobulin gene rearrangement analysis, 8 cytogenetic preparation and analysis, 9 ,10 viral and mycoplasmal evaluation. 6, 11 The immunomarkers employed are summarized in Table 1 . The following cytokines listed below in alphabetical order were used: bFGF (basic fibroblast growth factor ), EPO (erythropoietin), FLT3L (FLT3 ligand), G-CSF (granulocyte-CSF), GM-CSF, HGF (hepatocyte growth factor), IGF-I/II (insulin-like growth factor-I/II), IFN-␣ (interferon-␣), IFN-␤, IFN-␥, IL-1␣, IL-2 to IL-6, IL-8 to IL-13, IL-15, LIF (leukemia inhibitory factor), M-CSF (macrophage-CSF), OSM (oncostatin M), PIXY-321 (fusion protein of GM-CSF and IL-3), TGF-␤1 (tumor growth factor-␤1), TNF-␣ (tumor necrosis factor-␣), TNF-␤, and TPO (thrombopoietin). Cytokines were obtained from Roche (Mannheim, Germany) R&D Systems (Wiesbaden, Germany), and Immunex (Seattle, WA, USA). Further details on these cytokine experiments have been described previously. 7, 9 The following viruses were examined as described in detail elsewhere:
6 EBV (Epstein-Barr virus), HBV (hepatitis B virus), HCV (hepatitis C virus), HIV (human immunodeficiency virus), HTLV-I/II (human T cell leukemia/lymphoma virus). 
Results and discussion
A human leukemia cell line, named MUTZ-5, was established from the peripheral blood of a 26-year-old man with BCP-ALL at relapse in 1998. The simultaneous sister cell lines MUTZ-6 and MUTZ-7 which were derived independently, but from the same original peripheral blood cell sample showed similar or identical features. Pertinent cell culture characteristics of MUTZ-5 are summarized in Table 2 . MUTZ-5 cells were found to be negative for EBV and other viruses (Table 2) and also for mycoplasma. Authentication was verified by DNA fingerprinting confirming derivation from the primary cells and by cytogenetic analysis documenting the same unique chromosomal translocation in the primary cells and in the cell line. MUTZ-5 is a continuous cell line being grown in culture for more than 15 months. The main characteristics of these cells (as described below) remained the same for about 1 year of continuous culture, as well as after freezing and thawing. The cell line grows in suspension, as single cells or in clumps. MUTZ-5 cells are of variable size and shape and of heterogenous morphology, from small round to large polygonal cells; the cytoplasm is only weakly basophilic with occasional vacuoles; most cells contain only one nucleus which is commonly irregularly formed (clefted, indented, or kidney-shaped) with one or two prominent nucleoli; there is a high nuclear-to-cytoplasmic ratio (Figure 1) .
The immunomarker profile of the cell line is summarized in Table 1 . The cells expressed typical B cell-associated markers on the membrane surface and intracytoplasmatically such as CD10, CD19, CD20, CD22, CD37, CD40, cyCD79a, and cyCD79b. As the cells were surface immunoglobulin (smIg)-negative, the cells can be classified as precursor B cell line of type B-II (common B cell line) according to the EGIL classification. 12 Except for CD33, all T/NK cell, myelomonocytic, erythroid and megakaryocytic markers were found to be negative. Several activation and progenitor cell markers (CD30, CD34, CD38, CD71, HLA-DR, TdT) were detected on MUTZ-5 cells. Of the cytokine receptors analyzed, MUTZ-5 expresses receptors for IFN-␥ (CD119), IL-7 (CD127) and FLT3L (CD135). The B cell nature of MUTZ-5 cells was confirmed by the receptor gene rearrangement analysis whereby one of the immunoglobulin heavy chain genes was found to be rearranged, while the other was deleted; the kappa light chain genes had remained in germline configuration.
Despite receptor expression, IFN-␥, IL-7 or FLT3L did not enhance proliferation (maximum proliferation: only 110-120% of values for untreated control cells), nor did any other of the 27 stimulatory cytokines examined (listed in Materials and methods). The cytokines IL-4, TGF-␤1, TNF-␣ and TNF-␤ had proliferation-inhibiting effects; maximum inhibition: 20-70% compared with untreated control cells.
Giemsa-banding cytogenetics showed the following karyotype which was identical in all three sister cell lines and which was present throughout during the culturing of the cells: 45Ͻ2nϾX, −Y, t(12;13)(p12;q13-14) (Figure 2 ). An already known target gene at the 12p breakpoint is ETV6. The primary cells from which the cell line was established were
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Figure 2
Morphology of MUTZ-5 cells. Cytospin slide preparations of MUTZ-5 cells were stained with May-Grü nwald-Giemsa stain. Photograph was taken with a Nikon Labophot photomicroscope (Nikon, Dü sseldorf, Germany) using oil immersion and a ×63 objective.
found to carry a break within the ETV6 YAC (patient No. 10 in Ref. 13 ). Chromosome band 12p13 had been known to be involved in many different balanced leukemic translocations (reviewed in Ref. 14) . The fusion gene was cloned and initially termed TEL (for 'translocation ets leukemia') and later renamed ETV6 (for 'ets translocation variant gene 6'). ETV6 is now known to have many different fusion partners. 14 The most common partner of ETV6 is AML1 (renamed RUNX1) in the t(12;21)(p13;q22), 15 giving rise to the fusion gene ETV6-RUNX1 (reviewed in Ref. 16) . Work is in progress to clone the breakpoint on 13q which has been mapped adjacent to D13S25.
Clearly the scientific significance of the MUTZ-5 cell line lies in the t (12;13) . The salient features of cell line MUTZ-5 are summarized in Table 2 .
